Pulling SEC filings + quote and writing the call…

Jazz Pharmaceuticals plc
Next earnings Aug 3, 2026 · consensus $6.30 EPS, $1.13B rev
Last earnings +2.0% on 2026-05-05
Jazz's rare-disease engine still threw off $1.36B of cash on growing sales, but a GAAP net loss and $5.4B of debt keep this a show-me story.
Sources: SEC EDGAR (CIK 0001232524, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 8:46:34 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Jazz Pharmaceuticals is a profitable cash machine masquerading, for one year, as a loss-maker. FY2025 revenue grew 4.9% to $4.27B — the fifth straight year of growth from $3.09B in FY2021 — on a genuinely diversified rare-disease and oncology portfolio: Xywav and Epidiolex in sleep and epilepsy, plus a widening oncology franchise (Zepzelca in SCLC, Ziihera in HER2+ biliary cancer, and the newly launched Modeyso and Rylaze). Critically, operating cash flow held at $1.36B (down just 2.9%), so the business is generating substantial real cash even though it reported a -$356M net loss and -$5.84 diluted EPS.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B |
| Gross profit | — | — | — | — | — |
| Operating income | $170M | -$65.5M | $579M | $717M | -$430M |
| Net income | -$330M | -$224M | $415M | $560M | -$356M |
| Diluted EPS | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
| Net margin | -10.7% | -6.1% | 10.8% | 13.8% | -8.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1046 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 6 sales
| 2026-06-15 | Smith Mark Douglas Director | Sell | 1.16K @ $230.55 | $267K |
| 2026-06-10 | Patil Neena M EVP & Chief Legal Officer | Sell | 1.20K @ $231.83 | $278K |
| 2026-06-03 | GALA RENEE D President & CEO | Gift | 600.00 | |
| 2026-06-01 | COZADD BRUCE C Director | Sell | 6.00K @ $235.12 | $1.41M |
| 2026-05-28 | Patil Neena M EVP & Chief Legal Officer | Sell | 1.19K @ $236.97 | $282K |
| 2026-05-28 | Pearce Samantha EVP, Chief Commercial Officer | Exercise | 6.91K @ $109.45 | $756K |
| 2026-05-28 | Pearce Samantha EVP, Chief Commercial Officer | Sell | 6.91K @ $235.41 | $1.63M |
| 2026-05-28 | Mulligan Seamus Director | Exercise | 3.42K @ $138.08 | $472K |
| 2026-05-22 | Winningham Rick E Director | Exercise | 3.42K @ $138.08 | $472K |
| 2026-05-22 | Winningham Rick E Director | Sell | 2.74K @ $241.57 | $662K |